Research progress on the drug resistance and mechanism of the anti-tuberculosis drug bedaquiline

doi:10.19982/j.issn.1000-6621.20220122

Abstract

Abstract:

With the increase of multidrug-resistant tuberculosis (MDR-TB) and extensively drug-resistant tuberculosis (XDR-TB) strains, drug resistance of Mycobacterium tuberculosis (MTB) has become an urgent problem worldwide. Bedaquiline (Bdq) is the first new drug specifically in the treatment of MDR-TB in recent 50 years, and its drug resistance been gradually concerned. The research progress of drug resistance characteristics and drug resistance gene mutations of Bdq were reviewed, in order to better guide clinical medication, improve the success rate of treatment, and reduce the occurrence of drug resistance.

Key words: Tuberculosis, Drug resistance, Bedaquiline, Review literature as topic

CLC Number:

R52
R978.3

Yao Rong, Lu Yu. Research progress on the drug resistance and mechanism of the anti-tuberculosis drug bedaquiline[J]. Chinese Journal of Antituberculosis, 2022, 44(9): 973-977. doi: 10.19982/j.issn.1000-6621.20220122

References 41

[1]	World Health Organization. Global tuberculosis report 2021. Geneva: World Health 0rganization,2021.
[2]	Koul A, Vranckx L, Dhar N, et al. Delayed bactericidal response of Mycobacterium tuberculosis to bedaquiline involves remodelling of bacterial metabolism. Nat Commun, 2014, 5:3369. doi: 10.1038/ncomms4369. doi: 10.1038/ncomms4369 URL
[3]	中华医学会结核病学分会. 抗结核新药贝达喹啉临床应用专家共识(2020年更新版). 中华结核和呼吸杂志, 2021, 44(2):81-87. doi: 10.3760/cma.j.cn112147-20200714-00805. doi: 10.3760/cma.j.cn112147-20200714-00805
[4]	王晓英, 罗明, 张汇征, 等. 结核分枝杆菌贝达喹啉和氯法齐明耐药及其交叉耐药机制研究进展. 中国人兽共患病学报, 2022, 38(2):165-169. doi: 10.3969/j.issn.1002-2694.2021.00.031. doi: 10.3969/j.issn.1002-2694.2021.00.031
[5]	World Health Organization. The Use of Bedaquiline in the Treatment of Multidrug-Resistant Tuberculosis: Interim Policy Guidance. Geneva: World Health Organization, 2013.
[6]	Diacon AH, Pym A, Grobusch MP, et al. Multidrug-resistant tuberculosis and culture conversion with bedaquiline. N Engl J Med, 2014, 371(8):723-732. doi: 10.1056/NEJMoa1313865. doi: 10.1056/NEJMoa1313865 URL
[7]	Pontali E, Sotgiu G, D’Ambrosio L, et al. Bedaquiline and multidrug-resistant tuberculosis: a systematic and critical analysis of the evidence. Eur Respir J, 2016, 47(2):394-402. doi: 10.1183/13993003.01891-2015. doi: 10.1183/13993003.01891-2015 URL
[8]	Mirzayev F, Viney K, Linh NN, et al. World Health Organization recommendations on the treatment of drug-resistant tuberculosis, 2020 update. Eur Respir J, 2021, 57(6):2003300. doi: 10.1183/13993003.03300-2020. doi: 10.1183/13993003.03300-2020
[9]	Singh P, Kumari R, Lal R. Bedaquiline: Fallible Hope Against Drug Resistant Tuberculosis. Indian J Microbiol, 2017, 57(4):371-377. doi: 10.1007/s12088-017-0674-0. doi: 10.1007/s12088-017-0674-0 URL
[10]	Wu SH, Chan HH, Hsiao HC, et al. Primary Bedaquiline Resistance Among Cases of Drug-Resistant Tuberculosis in Taiwan. Front Microbiol, 2021, 12:754249. doi: 10.3389/fmicb.2021.754249. doi: 10.3389/fmicb.2021.754249 URL
[11]	He W, Liu C, Liu D, et al. Prevalence of Mycobacterium tuberculosis resistant to bedaquiline and delamanid in China. J Glob Antimicrob Resist, 2021, 26:241-248. doi: 10.1016/j.jgar.2021.06.007. doi: 10.1016/j.jgar.2021.06.007 URL
[12]	Huang H, Ding N, Yang T, et al. Cross-sectional Whole-genome Sequencing and Epidemiological Study of Multidrug-resistant Mycobacterium tuberculosis in China. Clin Infect Dis, 2019, 69(3):405-413. doi: 10.1093/cid/ciy883. doi: 10.1093/cid/ciy883 URL
[13]	Liu Y, Gao M, Du J, et al. Reduced Susceptibility of Mycobacterium tuberculosis to Bedaquiline During Antituberculosis Treatment and Its Correlation With Clinical Outcomes in China. Clin Infect Dis, 2021, 73(9):e3391-e3397. doi: 10.1093/cid/ciaa1002. doi: 10.1093/cid/ciaa1002
[14]	Ismail NA, Omar SV, Joseph L, et al. Defining Bedaquiline Susceptibility, Resistance, Cross-Resistance and Associated Genetic Determinants: A Retrospective Cohort Study. EBioMedicine, 2018, 28:136-142. doi: 10.1016/j.ebiom.2018.01.005. doi: S2352-3964(18)30005-7 pmid: 29337135
[15]	Veziris N, Bernard C, Guglielmetti L, et al. Rapid emergence of Mycobacterium tuberculosis bedaquiline resistance: lessons to avoid repeating past errors. Eur Respir J, 2017, 49(3):1601719. doi: 10.1183/13993003.01719-2016. doi: 10.1183/13993003.01719-2016
[16]	Peretokina IV, Krylova LY, Antonova OV, et al. Reduced susceptibility and resistance to bedaquiline in clinical M.tuberculosis isolates. J Infect, 2020, 80(5):527-535. doi: 10.1016/j.jinf.2020.01.007. doi: S0163-4453(20)30031-1 pmid: 31981638
[17]	Kaniga K, Hasan R, Jou R, et al. Bedaquiline Drug Resistance Emergence Assessment in Multidrug-Resistant Tuberculosis (MDR-TB): a 5-Year Prospective In Vitro Surveillance Study of Bedaquiline and Other Second-Line Drug Susceptibility Testing in MDR-TB Isolates. J Clin Microbiol, 2022, 60(1):e291920. doi: 10.1128/JCM.02919-20. doi: 10.1128/JCM.02919-20
[18]	Mallick JS, Nair P, Abbew ET, et al. Acquired bedaquiline resistance during the treatment of drug-resistant tuberculosis: a systematic review. JAC Antimicrob Resist, 2022, 4(2):dlac029. doi: 10.1093/jacamr/dlac029. doi: 10.1093/jacamr/dlac029 URL
[19]	Kunkel A, Cobelens FG, Cohen T. Tradeoffs in Introduction Policies for the Anti-Tuberculosis Drug Bedaquiline: A Model-Based Analysis. PLoS Med, 2016, 13(10):e1002142. doi: 10.1371/journal.pmed.1002142. doi: 10.1371/journal.pmed.1002142 URL
[20]	Nimmo C, Millard J, van Dorp L, et al. Population-level emergence of bedaquiline and clofazimine resistance-associated variants among patients with drug-resistant tuberculosis in southern Africa: a phenotypic and phylogenetic analysis. Lancet Microbe, 2020, 1(4):e165-e174. doi: 10.1016/S2666-5247(20)30031-8. doi: 10.1016/S2666-5247(20)30031-8
[21]	Ghodousi A, Rizvi AH, Baloch AQ, et al. Acquisition of Cross-Resistance to Bedaquiline and Clofazimine following Treatment for Tuberculosis in Pakistan. Antimicrob Agents Chemother, 2019, 63(9):e00915-19. doi: 10.1128/AAC.00915-19. doi: 10.1128/AAC.00915-19
[22]	Mokrousov I, Akhmedova G, Molchanov V, et al. Frequent acquisition of bedaquiline resistance by epidemic extensively drug-resistant Mycobacterium tuberculosis strains in Russia during long-term treatment. Clin Microbiol Infect, 2021, 27(3):478-480. doi: 10.1016/j.cmi.2020.08.030. doi: 10.1016/j.cmi.2020.08.030 URL
[23]	Kendall EA, Fofana MO, Dowdy DW. Burden of transmitted multidrug resistance in epidemics of tuberculosis: a transmission modelling analysis. Lancet Respir Med, 2015, 3(12):963-972. doi: 10.1016/S2213-2600(15)00458-0. doi: 10.1016/S2213-2600(15)00458-0 pmid: 26597127
[24]	Hartkoorn RC, Uplekar S, Cole ST. Cross-resistance between clofazimine and bedaquiline through upregulation of MmpL5 in Mycobacterium tuberculosis. Antimicrob Agents Chemother, 2014, 58(5):2979-2981. doi: 10.1128/AAC.00037-14. doi: 10.1128/AAC.00037-14 pmid: 24590481
[25]	Kadura S, King N, Nakhoul M, et al. Systematic review of mutations associated with resistance to the new and repurposed Mycobacterium tuberculosis drugs bedaquiline, clofazimine, linezolid, delamanid and pretomanid. J Antimicrob Chemother, 2020, 75(8):2031-2043. doi: 10.1093/jac/dkaa136. doi: 10.1093/jac/dkaa136 pmid: 32361756
[26]	Zimenkov DV, Nosova EY, Kulagina EV, et al. Examination of bedaquiline- and linezolid-resistant Mycobacterium tuberculosis isolates from the Moscow region. J Antimicrob Chemother, 2017, 72(7):1901-1906. doi: 10.1093/jac/dkx094. doi: 10.1093/jac/dkx094 pmid: 28387862
[27]	Pang Y, Zong Z, Huo F, et al. In Vitro Drug Susceptibility of Bedaquiline, Delamanid, Linezolid, Clofazimine, Moxifloxacin, and Gatifloxacin against Extensively Drug-Resistant Tuberculosis in Beijing, China. Antimicrob Agents Chemother, 2017, 61(10):e00900-17. doi: 10.1128/AAC.00900-17. doi: 10.1128/AAC.00900-17
[28]	Ghodousi A, Hussain RA, Khanzada FM, et al. In vivo microevolution of Mycobacterium tuberculosis and transient emergence of atpE_Ala63Pro mutation during treatment in a pre-XDR TB patient. Eur Respir J, 2022, 59(3):2102102. doi: 10.1183/13993003.02102-2021. doi: 10.1183/13993003.02102-2021
[29]	Gomez-Gonzalez PJ, Perdigao J, Gomes P, et al. Genetic diversity of candidate loci linked to Mycobacterium tuberculosis resistance to bedaquiline, delamanid and pretomanid. Sci Rep, 2021, 11(1):19431. doi: 10.1038/s41598-021-98862-4. doi: 10.1038/s41598-021-98862-4 URL
[30]	Omar SV, Ismail F, Ndjeka N, et al. Bedaquiline-Resistant Tuberculosis Associated with Rv0678 Mutations. N Engl J Med, 2022, 386(1):93-94. doi: 10.1056/NEJMc2103049. doi: 10.1056/NEJMc2103049 URL
[31]	Miotto P, Zhang Y, Cirillo DM, et al. Drug resistance mechanisms and drug susceptibility testing for tuberculosis. Respirology, 2018, 23(12):1098-1113. doi: 10.1111/resp.13393. doi: 10.1111/resp.13393 pmid: 30189463
[32]	Kaniga K, Aono A, Borroni E, et al. Validation of Bedaquiline Phenotypic Drug Susceptibility Testing Methods and Breakpoints: a Multilaboratory, Multicountry Study. J Clin Microbiol, 2020, 58(4):e01677-19. doi: 10.1128/JCM.01677-19. doi: 10.1128/JCM.01677-19
[33]	Gashaw F, Erko B, Mekonnen Y, et al. Phenotypic and genotypic drug sensitivity profiles of Mycobacterium tuberculosis infection and associated factors in northeastern Ethiopia. BMC Infect Dis, 2021, 21(1):261. doi: 10.1186/s12879-021-05961-8. doi: 10.1186/s12879-021-05961-8 pmid: 33711936
[34]	Tiberi S, Cabibbe AM, Tomlins J, et al. Bedaquiline Phenotypic and Genotypic Susceptibility Testing, Work in Progress!EBioMedicine, 2018, 29:11-12. doi: 10.1016/j.ebiom.2018.02.006. doi: 10.1016/j.ebiom.2018.02.006
[35]	World Health Organization. Technical Report on Critical Concentrations for Drug Susceptibility Testing of Medicines Used in the Treatment of Drug-Resistant Tuberculosis. Geneva: World Health Organization, 2018.
[36]	The European Committee on Antimicrobial Susceptibility Testing. Breakpoint Tables for Interpretation of Mics and Zone Diameters.Switzerland: 2020.
[37]	Ismail N, Riviere E, Limberis J, et al. Genetic variants and their association with phenotypic resistance to bedaquiline in Mycobacterium tuberculosis: a systematic review and individual isolate data analysis. Lancet Microbe, 2021, 2(11):e604-e616. doi: 10.1016/s2666-5247(21)00175-0. doi: 10.1016/s2666-5247(21)00175-0
[38]	Degiacomi G, Sammartino JC, Sinigiani V, et al. In vitro Study of Bedaquiline Resistance in Mycobacterium tuberculosis Multi-Drug Resistant Clinical Isolates. Front Microbiol, 2020, 11:559469. doi: 10.3389/fmicb.2020.559469. doi: 10.3389/fmicb.2020.559469 URL
[39]	Zhang S, Chen J, Cui P, et al. Identification of novel mutations associated with clofazimine resistance in Mycobacterium tuberculosis. J Antimicrob Chemother, 2015, 70(9):2507-2510. doi: 10.1093/jac/dkv150. doi: 10.1093/jac/dkv150 pmid: 26045528
[40]	Almeida D, Ioerger T, Tyagi S, et al. Mutations in pepQ Confer Low-Level Resistance to Bedaquiline and Clofazimine in Mycobacterium tuberculosis. Antimicrob Agents Chemother, 2016, 60(8):4590-4599. doi: 10.1128/AAC.00753-16. doi: 10.1128/AAC.00753-16 pmid: 27185800
[41]	Ismail NA, Omar SV, Moultrie H, et al. Assessment of epidemiological and genetic characteristics and clinical outcomes of resistance to bedaquiline in patients treated for rifampicin-resistant tuberculosis: a cross-sectional and longitudinal study. Lancet Infect Dis, 2022, 22(4):496-506. doi: 10.1016/S1473-3099(21)00470-9. doi: 10.1016/S1473-3099(21)00470-9 URL